X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SBCH: Uninterrupted growth but… - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Nov 29, 2000

    SBCH: Uninterrupted growth but…

    SmithKline Beecham Consumer Healthcare (SBCH) has reported satisfactory financial growth over the last three years. After the acquisition of Maltova and Viva, the company became the leader in the health food drink market. It enjoys a market share of over 70% with its leading brands Horlicks and Boost.

    The sheen of SBCH has not dimmed even during the slowdown in the economy and multiplying competition. Competition in the market for malted beverages failed to make a dent in the company’s markets share. In the past 3 years, SBCH’s profits have grown at a compounded annual growth rate (CAGR) of 21.6% while turnover witnessed a CAGR of 12.7%. The company’s profit margins are highest in the industry.

    Financial Performance
    Year ended December 31 9 months 3 years
    (Rs m) 1998 1999 2000 CAGR
    Sales 4,868 5,223 6,187 12.7%
    Other Income 170 192 206 10.0%
    Total Income 5,038 5,414 6,393 12.6%
    Operating Profit 902 1,012 1,264 18.4%
    Depreciation 61 75 106 32.3%
    Profit Before Tax 841 956 1,123 15.5%
    Tax 281 281 294 2.3%
    Profit After Tax 561 675 829 21.6%

    Key Ratios
    Particulars 9m 98 9m 99 9m 00
    Operating profit margins 15.0% 15.7% 17.1%
    Tax / PBT 33.3% 29.4% 26.2%
    Net profit margins 11.1% 12.5% 13.0%
    Cash EPS (Rs) 18.21 21.97 27.40
    EPS (Rs) 16.43 19.79 24.29
    *9m – Nine months

    However, during the third quarter ended September 2000, SBCH’s profit growth was affected by higher raw material prices (milk powder and milk fluid) and increase in promotional expenditure. The company’s excellent working capital management has enabled it to maintain its operating margins at the current level despite of increase in key costs.

    SBCH has amongst the lowest ad spent to sales ratio in the industry. The interesting fact to note is that during the past five years its sales grew at a faster rate than the growth in the advertising expenses. This is remarkable in the scenario of stiff competition where the companies are forced to spend more on promotional expenses in order to boost sales volumes.

    Sales outperforms ad spends
    Particulars SBCH Cadbury Nestle Britannia HLL
    5 yrs Advt. Exps CAGR 17.3% 29.1% 26.4% 35.9% 60.4%
    5 yrs. Sales CAGR 18.4% 19.2% 11.6% 18.7% 31.7%
    Advt. Exps as a % to sales 6.2% 10.2% 7.3% 6.8% 6.5%

    At the current market price of Rs 417, SBCH is trading at a P/E of 17 times its December 2000 projected earnings with a market cap to sales ratio of 2.2 times. The reasons for the company’s lower valuations compared to its peers in the industry are concerns about its parent’s 100% subsidiary. This subsidiary owns the leading oral care brand ‘Aquafresh’ and anti allergic brand ‘Crocin’. Also the fact that its parent imposed a 3.5% royalty on sales for the use of its technology has not gone down well with the investors.

    The investor community is also worried about the future of SBCH in India in light of the parent’s merger with Glaxo worldwide. In India Glaxo is known for its pharma focus and as such there is uncertainty on what it decides to do with SBCH. However, if any of the major FMCG companies like HLL, Nestle or Cadbury were to acquire SBCH from Glaxo, the stock could see a re-rating.

     

     

    Equitymaster requests your view! Post a comment on "SBCH: Uninterrupted growth but…". Click here!

      
     

    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    GSK Consumer: Feeling the Growth Pressures? (Quarterly Results Update - Detailed)

    Feb 15, 2016

    GSK Consumer Healthcare announced its results for the quarter ended December 2015. While revenues were up by 2% YoY, profits were higher by 37% YoY.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK CONSUMER SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK GSK CONSUMER

    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK CONSUMER 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE GSK CONSUMER WITH

    MARKET STATS